FibroGen Secures $160M to Fast-Track Next-Generation Therapeutics and Global Impact

FibroGen is thrilled to announce that we have successfully raised $160,000,000 in new funding, marking a significant milestone in our pursuit of developing transformative therapies for patients around the world. As a company dedicated to discovering, developing, and commercializing a pipeline of first-in-class therapeutics, this capital infusion reinforces our commitment to changing lives and fostering a thriving environment for both our people and our science. Our pioneering expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology has positioned us at the forefront of innovative research, and these new funds will be strategically deployed to advance both our clinical development and research capabilities. In particular, the investment will accelerate the progress of key clinical candidates such as pamrevlumab, an anti-CTGF human monoclonal antibody currently being evaluated for the treatment of locally advanced unresectable pancreatic cancer and Duchenne muscular dystrophy, as well as roxadustat, the first-in-class oral medication for anemia of chronic kidney disease that has already seen regulatory success across major international markets. Additionally, the funding will support our recent expansion into immuno-oncology and autoimmune diseases, promising potential new avenues for addressing significant unmet medical needs. We are excited about the future and remain wholeheartedly committed to making a difference for patients suffering from conditions like anemia, fibrotic disease, and cancer. To learn more about our innovative work and our company culture, please visit https://www.fibrogen.com/our-culture. Also, please note that all approved FibroGen positions are available only on our Careers page at www.fibrogen.com/careers, in light of recent warnings regarding fraudulent remote job postings.